Please assess the completion status of the following clinical trial:

Trial Title: Glucophage Immediate Release (GIR) China Bioequivalence Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants had given written informed consent before any trial-related activities~* Chinese male and female participants (at least 1/4 of each gender per trial group)~* Aged between 18 and 55 years, inclusive~* Weighed: 50 to 80 kilogram (kg); Body mass index (BMI): 18 to 30 kg per meter square~* Nonsmoker since at least 3 months~* Good physical and mental health status, determined on the basis of the medical history and a physical examination~* All values for biochemistry and hematology tests of blood and urine within the normal range or showied no clinically relevant deviation as judged by the Investigator~* Electrocardiogram recording (12-lead ECG) without signs of clinically relevant pathology was judged by the Investigator~* Vital signs (blood pressure, pulse, body temperature, and respiration) in sitting position within the normal range or showing no clinically relevant deviation was judged by the Investigator~* All women of childbearing potential (WOCBP) who were not nursing, were not pregnant, and were using highly effective methods of birth control~* Negative screen for alcohol and drugs of abuse (cannabis, benzodiazepines, barbiturates, opiates, cocaine, and methyl amphetamine) were screened at and on admission~* Negative screen for hepatitis A virus (HAV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV) antibodies, and Treponema pallidum (TP) antibodies~Exclusion Criteria:~* Participation in a clinical trial within 90 days prior to first drug administration~* Blood donation (equal or more than 500 milliliter \[mL\]) or significant blood loss within 90 days prior to first drug administration~* Any surgical or medical condition, including findings in the medical history or in the pretrial assessments, or any other significant disease, that in the opinion of the Investigator, constitutes a risk or a contraindication for the participation of the participant in the trial or that could interfere with the trial objectives, conducted or evaluated~* History of surgery of the gastrointestinal tract which could influence the gastrointestinal absorption and/or motility according to the Investigator's opinion~* History or presence of relevant liver diseases or hepatic dysfunction Allergy: ascertained or presumptive hypersensitivity to the active drug substance and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considered affectted the outcome of the trial~* Receipt of any prescription or nonprescription medication within 2 weeks before the first IMP administration, including multivitamins and herbal products (example, St John's Wort, or traditional Chinese medicines), except paracetamol~* Renal failure or renal dysfunction (creatinine clearance \< 80 mL/minute) as assessed by using the estimated measure with the Modification of Diet in Renal Disease (MDRD) equation~* Known lack of participant compliance or inability to communicate or cooperate with the Investigator (example, language problem and poor mental status)~* Nonacceptance of trial high-fat breakfast (example, vegetarians, vegans, and participants followed special diets)~* Consumption of large quantities of methyl xanthine-containing beverages (\> 5 cups of coffee/day or equivalent)~* Consumption of grapefruit, cranberry or juices of these fruits, from 14 days prior to drug administration until collection of the last pharmacokinetic sample in Period 2~* Any contraindication to Glucophage~* Abnormal and clinically significant chest X-ray finding at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- First Test GIR (Fasting), Then Reference GIR (Fasting) (Type: EXPERIMENTAL): Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
- First Reference GIR (Fasting), Then Test GIR (Fasting) (Type: EXPERIMENTAL): Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
- First Test GIR (Fed), Then Reference GIR (Fed) (Type: EXPERIMENTAL): Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
- First Reference GIR (Fed), Then Test GIR (Fed) (Type: EXPERIMENTAL): Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).